Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

E2F1 death pathways as targets for cancer therapy.

B M Pützer1

  • 1Department of Vectorology and Experimental Gene Therapy, University of Rostock, Biomedical Research Center, Schillingallee 69, D-18055 Rostock, Germany. brigitte.puetzer@med.uni-rostock.de

Journal of Cellular and Molecular Medicine
|May 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.

Oncogene·2014
Same author

Immune responses to RHAMM in patients with acute myeloid leukemia after chemotherapy and allogeneic stem cell transplantation.

Clinical & developmental immunology·2012
Same author

Adenoviral transduction supports matrix expression of alginate cultured articular chondrocytes.

Biotechnology and bioengineering·2012
Same author

Evaluation of systemic targeting of RET oncogene-based MTC with tumor-selective peptide-tagged Ad vectors in clinical mouse models.

Gene therapy·2011
Same author

GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria.

Cell death and differentiation·2010
Same author

Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.

Endocrine-related cancer·2008

Defects in apoptosis, a programmed cell death, are linked to diseases and treatment failure. The E2F1 transcription factor acts as a tumor surveillance factor, regulating cell death to prevent tumor development.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cell Biology

Background:

  • Apoptosis (programmed cell death) defects are implicated in human diseases like neurodegeneration and cancer.
  • Cell number regulation is influenced by factors affecting cell survival and death.
  • The E2F1 transcription factor is a critical regulator of apoptotic pathways.

Purpose of the Study:

  • To explore the role of E2F1 in regulating apoptotic programs.
  • To understand how E2F1-induced cell death contributes to tumor surveillance.
  • To identify novel factors influencing E2F1-mediated apoptosis for therapeutic strategies.

Main Methods:

  • Investigating the genetic basis of apoptosis.
  • Analyzing E2F1's role in cell death pathways, both p53-dependent and independent.

Related Experiment Videos

  • Identifying novel players in E2F1-controlled apoptosis.

    • Main Results:

    • E2F1 induces cell death through multiple pathways.
    • E2F1 functions as a tumor surveillance factor by detecting aberrant proliferation.
    • E2F1-mediated apoptosis can occur independently of the tumor suppressor p53.

    Conclusions:

    • E2F1 plays a crucial role in preventing tumor development.
    • Understanding E2F1's mechanisms can lead to new therapeutic approaches for cancer and other diseases.
    • Further research into novel players will expand the interpretation of E2F1's role in apoptosis.